.

Karyopharm Therapeutics reported $302.69M in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Amgen AMGN:US $ 36522M 332M
AstraZeneca AZN:LN 2425311.81M 57309.55M
Astrazeneca AZN:US $ 29528M 1571M
Avrobio Inc AVRO:US $ 15.1M 84K
Biocryst Pharmaceuticals BCRX:US $ 622.18M 17.72M
Bristol Myers Squibb BMY:US $ 42060M 2912M
Eli Lilly And LLY:US $ 16813.8M 305M
Enanta Pharmaceuticals ENTA:US $ 1.51M 0M
Epizyme EPZM:US $ 232.9M 0.41M
GlaxoSmithKline GSK:LN 2211100M 1121700M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Macrogenics MGNX:US $ 0M 0M
Mirati Therapeutics MRTX:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Novartis NOVN:VX SF 31031M 244M
Novartis NVS:US $ 31031M 244M
Regeneron Pharmaceuticals REGN:US $ 2700.7M 0.3M
Sangamo Biosciences SGMO:US $ 0M 0M
Takeda 4502:JP Y 4602254M 256843M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Xencor XNCR:US $ 0M 0M
YTE INCY:US $ 34.19M 0.01M